Referenties

1. 2023 ESH Guidelines for the management of arterial hypertension. J Hypertens 2023;41:000–000 DOI:10.1097/HJH.0000000000003480.
2. European Heart Journal (2023) 00, 1–98.
3. ADVANCE Collaborative Group. Lancet 2007;370:829-40.
4. Lewis EJ et al. N Engl J Med 2001;345:851-60.
5. RENAAL Study Investigators. N Engl J Med 2001;345:861-9.
6. DIRECT Programme Study Group Lancet 2008; 372: 1385–93
7. Haller H et al. N Engl J Med 2011;364:907-17
8. Ferrari R and Boersma E. Exp. Rev. Cardiovasc Ther. 2013;11:705-717.
9. Taddei Am J Cardiovasc Drugs 2016;16:309–321.
10. RCP Preterax
11. RCP Triplixam

SPKs

1. Preterax
2. Triplixam

Publieksprijs

Wettelijke informatie

BNL HT BI 24 C2 GS 20 – Goedkeuringsdatum van de medische informatie: 10/04/2024